281 related articles for article (PubMed ID: 32943758)
21. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
22. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
23. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
24. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
25. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
26. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
Front Immunol; 2021; 12():707191. PubMed ID: 34349766
[TBL] [Abstract][Full Text] [Related]
27. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
[TBL] [Abstract][Full Text] [Related]
28. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
[TBL] [Abstract][Full Text] [Related]
29. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
30. Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy.
Martín-Antonio B
Front Immunol; 2021; 12():666703. PubMed ID: 33815428
[No Abstract] [Full Text] [Related]
31. Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.
Wang Y; Zhou Y; Yang Z; Xia D; Hu Y; Geng S
Respiration; 2020; 99(8):649-657. PubMed ID: 32841948
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib for treatment of CAR T-cell therapy-related complications.
Baur K; Heim D; Beerlage A; Poerings AS; Kopp B; Medinger M; Dirks JC; Passweg JR; Holbro A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455991
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
34. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
36. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Galli E; Sorà F; Hohaus S; Fresa A; Pansini I; Autore F; Metafuni E; Innocenti I; Limongiello MA; Giammarco S; Laurenti L; Bacigalupo A; Chiusolo P; De Stefano V; Sica S
Br J Haematol; 2023 Apr; 201(1):86-94. PubMed ID: 36503182
[TBL] [Abstract][Full Text] [Related]
37. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
Jamal FA; Khaled SK
Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
39. The Hyper-Inflammatory Response in Adults with Severe COVID-19 Pneumonia Differs from the Cytokine Storm of Hemophagocytic Syndrome.
Brikman S; Bieber A; Dori G
Isr Med Assoc J; 2020 Aug; 22(8):505-513. PubMed ID: 33236584
[TBL] [Abstract][Full Text] [Related]
40. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
